Therapeutic vaccination and novel strategies to treat chronic HBV infection

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 5, 2009, Pages 561-569

  Bertoletti, Antonio ^a,b,c   Gehring, Adam ^a  

^a AGENCY FOR SCIENCE   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

PD 1; T cell deletion; T cell exhaustion; T cell receptor therapy; Treg; Viral hepatitis

Indexed keywords

AS 02B; EPITOPE; GENHEVAC; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; LAMIVUDINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT HEPATITIS B VACCINE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADOPTIVE TRANSFER; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; BONE MARROW TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CHRONIC HEPATITIS; CHRONIC HEPATITIS B; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENE TRANSFER; HELPER CELL; HEPATITIS B; HUMAN; IMMUNITY; IMMUNOGENICITY; IMMUNOTHERAPY; INTRAUTERINE INFECTION; MONOTHERAPY; NEWBORN HEPATITIS; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SEROCONVERSION; T LYMPHOCYTE; VACCINATION; VIRUS REPLICATION;

HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNITY, INNATE; T-LYMPHOCYTE SUBSETS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 70449698040     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.48     Document Type: Review

References (78)

1. Dienstag JL. Hepatitis B virus infection. N. Engl. J. Med. 359, 1486-1500 (2008).
2. Bertoletti A, Naoumov NV. Translation of immunological knowledge into better treatments of chronic hepatitis B. J. Hepatol. 39(1), 115-124 (2003). (Pubitemid 36724117)
3. Ferrari C, Penna A, Bertoletti A et al. Cellular immune response to hepatitis B virus encoded antigens in acute and chronic hepatitis B virus infection. J. Immunol. 145, 3442-3449 (1990).
4. Jung M, Spengler U, Schraut W et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J. Hepatol. 13, 310-317 (1991).
5. Penna A, Artini M, Cavalli A et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J. Clin. Invest. 98(5), 1185-1194 (1996). (Pubitemid 26299932)
6. Penna A, Del Prete G, Cavalli A et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 25(4), 1022-1027 (1997). (Pubitemid 27157151)
7. Rehermann B, Fowler P, Sidney J et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J. Exp. Med. 181(3), 1047-1058 (1995).
8. + T-cell response between acute and chronic HBV-infected subjects.
9. Jung M, Hartmann B, Gerlach J et al. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology 261, 165-172 (1999). (Pubitemid 29431769)
10. Tan AT, Loggi E, Boni C et al. Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J. Virol. 82(22), 10986-10997 (2008). • Shows that the profile of the HBV-specific T-cell response is not influenced by ethnicity or route of HBV transmission.
11. Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest. 102(5), 968-975 (1998). (Pubitemid 28419565)
12. Boni C, Penna A, Bertoletti A et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J. Hepatol. 39(4), 595-605 (2003). (Pubitemid 37204661)
13. Cooksley H, Chokshi S, Wedemeyer H et al. Hepatitis B virus-specific T-cell reactivity during adefovir dipivoxil treatment: a multicentre controlled study. J. Hepatol. 36(Suppl. 1), 7 (2002).
14. Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 104(6), 1818-1821 (1993). • Demonstrates that reconstitution of an HBV-primed immune system can efficiently control chronic HBV infection in humans.
15. Lau GK, Lok AS, Liang RH et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 25(6), 1497-1501 (1997). • Demonstrates that reconstitution of an HBV-primed immune system can efficiently control chronic HBV infection in humans.
16. Lau GK, Suri D, Liang R et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 122(3), 614-624 (2002). • Demonstrates that reconstitution of an HBV-primed immune system can efficiently control chronic HBV infection in humans. (Pubitemid 34173812)
17. Loggi E, Bihl F, Chisholm III JV et al. Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft. J. Hepatol. 50, 625-630 (2009). • Further demonstrates that an HBV-primed immune system can clear the virus from an infected liver.
18. Menne S, Roneker CA, Korba BE, Gerin JL, Tennant BC, Cote PJ. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-β-Larabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J. Virol. 76(11), 5305-5314 (2002). (Pubitemid 34517881)
19. Rollier C, Sunyach C, Barraud L et al. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology 116, 658-665 (1999). (Pubitemid 29106774)
20. Pol S, Nalpas B, Driss F et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J. Hepatol. 34(6), 917-921 (2001). (Pubitemid 32595193)
21. Vandepapeliere P, Lau GKK, Leroux-Roels G et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by anti-viral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25, 8585-8597 (2007). • First large clinical trial exploring the therapeutic efficacy of the association of HBV vaccine with antiviral therapy. (Pubitemid 350192039)
22. Lu M, Yao X, Xu Y et al. Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J. Virol. 82(5), 2598-2603 (2008). (Pubitemid 351293564)
23. + T-cell proliferative response in chronic hepatitis B carriers. Vaccine 20(29-30), 3598-3612 (2002).
24. Rahaman F, Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. Cellular and humoral immune responses induced by intradermal or intramuscolar vaccination with the major hepatitis B surface antigen. Hepatology 31(2), 521-527 (2000). (Pubitemid 30078622)
25. Heathcote J, McHutchison J, Lee S et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 30, 531-536 (1999).
26. Vitiello A, Ishioka G, Grey HM et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95(1), 341-349 (1995).
27. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40(4), 874-882 (2004). (Pubitemid 39288120)
28. Yang SH, Lee CG, Im SJ et al. Correlation of antiviral T cell responses with supression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther. 13, 1110-1117 (2006).
29. Akbar SM, Murakami H, Horiike N, Onji M. Dendritic cell-based therapies in the bench and the bedsides. Curr. Drug Targets Inflamm. Allergy 3(3), 305-310 (2004). (Pubitemid 39206659)
30. Xu DZ, Zhao K, Guo LM et al. A randomized controlled Phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE 3(7), e2565 (2008).
31. Yao X, Zheng B, Zhou J et al. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 25(10), 1771-1779 (2007). (Pubitemid 46188371)
32. Lin YC, Chang MH, Ni YH, Hsu CH, Chen DS. Long term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J. Infect. Dis. 187, 134-138 (2003).
33. Beasley RP, Lee CK, Roan CH et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 2 (8359), 1099-1102 (1983).
34. Baht P, Anderson DA. Hepatitis B virus translocates across a trophoblastic barrier. J. Virol. 81, 7200-7207 (2007).
35. Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J. Pediatr. 133, 374-377 (1998).
36. Xu WM, Cui YT, Wang L et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J. Viral Hepatitis 16, 94-103 (2009).
37. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77(8), 4911-4927 (2003). • First description of the functional profile of exhausted T cells during chronic viral infection. (Pubitemid 36402840)
38. + T cell exhaustion during chronic viral infection. Immunity 27, 670-684 (2007).
39. Boni C, Fisicaro P, Valdatta C et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81(8), 4215-4225 (2007). • Describes functional alteration affecting HBV-specific CD8+ T cells of chronic hepatitis B patients. (Pubitemid 46586915)
40. + T cells of chronic hepatitis B patients.
41. Gehring A, Ho ZZ, Tan AT et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 137(2), 682-690 (2009).
42. Kakimi K, Isogawa M, Chung J, Sette A, Chisari FV. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J. Virol. 76(17), 8609-8620 (2002). (Pubitemid 34864055)
43. + T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J. Virol. 78(11), 5707-5719 (2004).
44. Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich D. The serology of chronic hepatitis B infection revisited. J. Clin. Invest. 91, 2586-2595 (1993). • Detailed analysis of the anti-HBV antibody response in chronic hepatitis B patients. (Pubitemid 23182513)
45. van Driel I, Ang D. The role of regulatory T cells in gastrointestinal inflammatory disease. J. Gastroenterol. Hepatol. 23(2) 171-177 (2008). (Pubitemid 351257680)
46. Li S, Gowans EJ, Chougnet C, Plebanski M, Dittmer U. Natural regulatory T cells and persistent viral infection. J. Virol. 82(1), 21-30 (2007).
47. Manigold T, Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect. Dis. 7(12), 804-813 (2007). • Comprehensive review exploring the impact of regulatory T cells in chronic viral hepatitis. (Pubitemid 350152043)
48. Bauer T, Gunther M, Bienzle U, Neuhaus R, Jilg W. Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells. Liver Transpl. 13(3), 434-442 (2007). (Pubitemid 46444473)
49. + regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Int. Immunol. 19(2), 133-140 (2007).
50. Kondo Y, Kobayashi K, Ueno Y et al. Mechanism of T cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B. World J. Gastroenterol. 12(27), 4310-4317 (2006). (Pubitemid 44194522)
51. + regulatory T cells in patients with hepatitis B virus infection. J. Virol. 79(6), 3322-3328 (2005).
52. + regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol. 177(1), 739-747 (2006).
53. Stoop JN, van der Molen RG, Baan CC et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41(4), 771-778 (2005).
54. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Ann. Rev. Immunol. 18, 767-811 (2000).
55. Lew YY, Michalak TI. In vitro and in vivo infectivity and pathogenicity of the lymphoid cell-derived woodchuck hepatitis virus. J. Virol. 75(4), 1770-1782 (2001).
56. Tavakoli S, Schwerin W, Rohwer A et al. Phenotype and function of monocyte derived dendritic cells in chronic hepatitis B virus infection. J. Gen. Virol. 85(Pt 10), 2829-2836 (2004). (Pubitemid 39360025)
57. Untergasser A, Zedler U, Langenkamp A et al. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 43(3), 539-547 (2006). • Describes the inability of dendritic cells to sustain HBV replication.
58. Wang FS, Xing LH, Liu MX et al. Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection. World J. Gastroenterol. 7(4), 537-541 (2001).
59. Beckebaum S, Cicinnati VR, Dworacki G et al. Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin. Immunol. 104(2), 138-150 (2002). (Pubitemid 35026224)
60. Lohr HF, Pingel S, Bocher WO, Bernhard H, Herzog-Hauff S, Rose-John S. Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - restoration by exogenous interleukin-12. Clin. Exp. Immunol. 130(1), 107-114 (2002).
61. van der Molen RG, Sprengers D, Binda RS et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 40(3), 738-746 (2004). (Pubitemid 39265597)
62. Chen L, Zhang Z, Chen W et al. B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J. Immunol. 178(10), 6634-6641 (2007). (Pubitemid 46717448)
63. Das A, Hoare M, Davies N et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J. Exp. Med. 205(9), 2111-2124 (2008).
64. Sällberg M, Hughes J, Javadian A et al. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum. Gene Ther. 9, 1719-1729 (1998). (Pubitemid 28418742)
65. Depla E, van der Aa A, Livingston B et al. Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J. Virol. 82, 435-450 (2008). • Describes the design and functional evaluation in mice of the first multi-epitope vaccine for the treatment of chronic HBV infection. (Pubitemid 350309158)
66. Riedl P, Bertoletti A, Lopes R, Lemonnier F, Reimann J, Schirmbeck R. Distinct, cross-reactive epitope specificities of CD8 T cell responses are induced by natural hepatitis B surface antigen variants of different hepatitis B virus genotypes. J. Immunol. 176, 4003-4011 (2006). (Pubitemid 44264378)
67. Nakamoto N, Cho H, Shaked A et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PloS Pathogens 5(2), e1000313 (2009).
68. Velu V, Titanji K, Zhu B et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458(7235), 206-210 (2009). • First in vivo demonstration that anti-PD1 blockade can restore virus-specific T-cell immunity during chronic viral infection.
69. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8, 239-245 (2007). (Pubitemid 46745373)
70. Bohne F, Chmielewski M, Ebert G et al. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 134, 239-247 (2008). • First publication describing the in vitro production of HBV-specific cells able to recognize infected hepatocytes.
71. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (2006).
72. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100, 182-188 (1991).
73. Caselitz M, Link H, Hein R et al. Hepatitis B associated liver failure following bone marrow transplantation. J. Hepatol. 27, 572-577 (1997). (Pubitemid 27390906)
74. Yeo W, Chan PK, Chan HL, Mo FK, Johnson PJ. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J. Med. Virol. 65, 473-477 (2001). (Pubitemid 32959072)
75. Yeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Virol. 62, 299-307 (2000). (Pubitemid 30740118)
76. Lau GK, Liang R, Wu PC, Lee CK, Lim WL, Au WY. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J. Hepatol. 28, 359-368 (1998). (Pubitemid 28133537)
77. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 100, 391-396 (2002). (Pubitemid 34761098)
78. Lau GK, He ML, Fong DY et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 36(3), 702-709 (2002).